IP Verse

Pharmaceutical Compositions Of Roflumilast In Aqueous Blends Of Water-Miscible, Pharmaceutically Acceptable Solvents - EP3684334

The patent EP3684334 was granted to Arcutis on Dec 6, 2023. The application was originally filed on Sep 19, 2018 under application number EP18783250A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3684334

ARCUTIS
Application Number
EP18783250A
Filing Date
Sep 19, 2018
Status
Granted And Under Opposition
Nov 3, 2023
Publication Date
Dec 6, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

TEVA PHARMACEUTICALSAug 13, 2024ELKINGTON AND FIFEADMISSIBLE

Patent Citations (19) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS20100846079
DESCRIPTIONEP1511516
DESCRIPTIONUS5712298
DESCRIPTIONUS6074670
DESCRIPTIONUS7951398
DESCRIPTIONUS8431154
DESCRIPTIONUS9205044
DESCRIPTIONUS9649302
DESCRIPTIONWO2013030789
DESCRIPTIONWO2015132708
DESCRIPTIONWO9501338
INTERNATIONAL-SEARCH-REPORTUS2007259009
INTERNATIONAL-SEARCH-REPORTUS2012252793
INTERNATIONAL-SEARCH-REPORTUS2014296191
OPPOSITIONUS2007259009
OPPOSITIONUS2012252793
OPPOSITIONUS2014296191
OPPOSITIONUS9907788
OPPOSITIONWO03099334

Non-Patent Literature (NPL) Citations (7) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- Adrian C. Williams, "39 Topical and transdermal drug delivery", Adrian C. Williams, Aulton M E, Taylor K M G (eds.), Aulton's Pharmaceutics: The Design and Manufacture of Medicines (4th edition), Elsevier , (20130101), pages 675 - 697, ISBN 978-0-7020-4290-4, XP009557335
OPPOSITION- Anonymous, "Efficient skin delivery: no compromise with Transcutol ®", Gattefossé, (20150101), XP093209649
OPPOSITION- Osborne David W, "Review of Changes in Topical Drug Product Classification", Pharmaceutical Technology, (20081002), Pharmaceutical Technology , URL: https://www.pharmtech.com/view/review-changes-topical-drug-product-classification, XP093209646
OPPOSITION- Rowe, Raymond C, "Diethylene Glycol Monoethyl Ether", Rowe, Raymond C, Raymond C Rowe, Paul J Sheskey, Walter G Cook, Marian E Fenton, Handbook of Pharmaceutical Excipients, 7th Edition, Pharmaceutical Press, (20120101), pages 256 - 258, ISBN 978-0-85711-027-5, XP009559799
OPPOSITION- D.W. Sullivan Jr. et al., "A review of the nonclinical safety of Transcutol, a highly purified form of diethylene glycol monoethyl ether (DEGEE) used as a pharmaceutical excipient", Food and Chemical Toxicology , (2014), vol. 72, doi:10.1016/j.fct.2014.06.028, XP029065626
OPPOSITION- S.D. Snape et al., "A phase I randomized trial to assess the effect on skin infiltrate thickness and tolerability of topical phosphodiesterase inhibitors in the treatment of psoriasis vulgaris using a modified psoriasis plaque test", British Journal of Dermatology, (20160901), vol. 175, no. 3, doi:10.1111/bjd.14634, pages 479 - 486, XP071119419
OPPOSITION- Lorimer J. W., "Thermodynamics of solubility in mixed solvent systems", PURE & APPLIED CHEMISTRY, PERGAMON PRESS, OXFORD, GB, GB , (19930101), vol. 65, no. 2, doi:10.1351/pac199365020183, ISSN 0033-4545, pages 183 - 191, XP093209637

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents